Avid Bioservices Inc (CDMO)

[biopharm]

Peregrine Pharmaceuticals and AstraZeneca

----

Sept 2012

We were pleased to announce today that we are joining nine of our industry peers as a founding member of TransCelerate BioPharma Inc. TransCelerate is an industry-wide collaboration aimed at developing shared research and development solutions to accelerate the delivery of innovative products to patients.

The group was founded on alignment among heads of R&D that there is a critical need to substantially increase the number and quality of innovative new medicines, while eliminating inefficiencies that drive up R&D costs and improving patient safety. Martin Mackay, head of R&D at AstraZeneca, had this to say about TBI:

http://www.labtalk.astrazeneca.com/collaboration/transcelerate-biopharma-inc/

----------------------------------------------------

Jan 2013

The new CEO at AstraZeneca ($AZN) has put together his top executive crew responsible for turning around the laggard pharma giant. And there was no room on board for R&D chief Martin Mackay. A little more than two years since Mackay was poached from Pfizer ($PFE), Pascal Soriot is eliminating the position of president of R&D while also bidding goodbye to Tony Zook and the now-extinct job of EVP, global commercial.

Mackay's departure comes after a year of turmoil at AstraZeneca, which has been hammered by investors and analysts who have been upset with the company's inability to piece together the kind of pipeline needed to position the company for the future. After CEO David Brennan was sacked last year, Mackay had vowed to pick up the deal pace. But his efforts clearly didn't win him much affection with the new boss.

Now the global R&D operation will be divvied among three key players: Mene Pangalos, MedImmune's Bahija Jallal and Briggs Morrison. They will each be given one of three tasks: Head of discovery and early development of small molecules, running early-stage work on biologics (MedImmune's role), and late-stage development.

http://www.fiercebiotech.com/r-d/astrazeneca-research-chief-mackay-ousted-executive-shakeup

--------------------------------------------------------

Aug/Sept 2015

Chief Medical Officer
AstraZeneca
September 2015 – Present (8 months)Gaithersburg, Maryland

https://www.linkedin.com/in/sean-bohen-md-phd-a625055

AstraZeneca lures Sean Bohen from Genentech to fill top R&D post

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116446416

-------------------------------------------------------

Dec 2015

Sean Bohen just jumped ship from Roche to join AZ in Sept 2015

"As previously communicated, the treatment and regulatory landscape in lung cancer is evolving," said Sean Bohen, the chief medical officer at AstraZeneca, in a statement. "We now believe it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast advancing development program focused primarily on novel combinations."

http://www.fiercebiotech.com/story/astrazeneca-hit-another-setback-durvalumab-disappoints-lung-cancer/2015-12-18

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119295066

---------------------------------------------------

I also now see Sean Bohen on the BOD over at Transcelerate and not sure when he arrived there....